---
title: The Oncology Biomarker Discovery framework reveals cetuximab and bevacizumab
  response patterns in metastatic colorectal cancer
date: '2023-09-04'
linkTitle: https://pubmed.ncbi.nlm.nih.gov/37666855/?utm_source=curl&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1FakS-2QOkCT8HsMOQP1bCRQ4YzyumYOmxmF0moLsQ3dFB1E9V&fc=20220326224207&ff=20230905181708&v=2.17.9.post6+86293ac
source: heidelberg[Affiliation]
description: Precision medicine has revolutionised cancer treatments; however, actionable
  biomarkers remain scarce. To address this, we develop the Oncology Biomarker Discovery
  (OncoBird) framework for analysing the molecular and biomarker landscape of randomised
  controlled clinical trials. OncoBird identifies biomarkers based on single genes
  or mutually exclusive genetic alterations in isolation or in the context of tumour
  subtypes, and finally, assesses predictive components by their ...
disable_comments: true
---
Precision medicine has revolutionised cancer treatments; however, actionable biomarkers remain scarce. To address this, we develop the Oncology Biomarker Discovery (OncoBird) framework for analysing the molecular and biomarker landscape of randomised controlled clinical trials. OncoBird identifies biomarkers based on single genes or mutually exclusive genetic alterations in isolation or in the context of tumour subtypes, and finally, assesses predictive components by their ...